<description>AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team

CME Available: https://cme.auanet.org/URL/PARP26ONL

LEARNING OBJECTIVES:
At the conclusion of this CME activity, participants will be able to:
1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination.
2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC.
3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC.
4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life.
5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment.
5. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 

Astrazeneca
Merck &amp; Co., Inc
Pfizer, Inc.</description>

AUA2026 Spotlight: PARP-Inhibitor Combination Tre…

AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team

CME Available: https://cme.auanet.org/URL/PARP26ONL

LEARNING OBJECTIVES:
At the conclusion of this CME activity, participants will be able to:
1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination.
2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC.
3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC.
4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life.
5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment.
5. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 

Astrazeneca
Merck & Co., Inc
Pfizer, Inc.

AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team

<description>Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines

Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026</description>

Update Series (2026) Lesson 15: Case-Based Testic…

Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines

Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines

<description>AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Jaspreet S. Sandhu, MD

To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bph-guideline.

Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.</description>

AUA Guidelines: Management of Lower Urinary Tract…

AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Jaspreet S. Sandhu, MD

To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bph-guideline.

Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.

AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to BPH

<description>AUA2026: Society of Women in Urology Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Amy N. Luckenbaugh, MD, FACS

To register for AUA2026, please visit auanet.org/AUA2026/register!</description>

AUA2026: Society of Women in Urology Meeting

Hos…

AUA2026: Society of Women in Urology Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Amy N. Luckenbaugh, MD, FACS

To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Women in Urology Meeting

<description>AUA2026: Society of Urologic Oncology Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Dr. Kelvin A. Moses, MD, PhD &amp; Dr. Mark A. Preston, MD, MPH

To register for AUA2026, please visit auanet.org/AUA2026/register!</description>

AUA2026: Society of Urologic Oncology Meeting

Ho…

AUA2026: Society of Urologic Oncology Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Dr. Kelvin A. Moses, MD, PhD & Dr. Mark A. Preston, MD, MPH

To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Urologic Oncology Meeting

The AUAUniversity podcast is an official podcast of the American Urological Association.  More information can be found at https://auau.auanet.org

AUAUniversity

Details

Recent Episodes